| The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies CN Baxevanis, SP Fortis, SA Perez Seminars in cancer biology 72, 76-89, 2021 | 169 | 2021 |
| The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer M Sofopoulos, SP Fortis, CK Vaxevanis, NN Sotiriadou, N Arnogiannaki, ... Cancer Immunology, Immunotherapy 68 (11), 1733-1745, 2019 | 148 | 2019 |
| Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer SP Fortis, M Sofopoulos, NN Sotiriadou, C Haritos, CK Vaxevanis, ... Journal for immunotherapy of cancer 5 (1), 39, 2017 | 100 | 2017 |
| Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes DC Watson, E Moysi, A Valentin, C Bergamaschi, S Devasundaram, ... PLoS pathogens 14 (2), e1006902, 2018 | 80 | 2018 |
| The role of immune infiltrates as prognostic biomarkers in patients with breast cancer CN Baxevanis, M Sofopoulos, SP Fortis, SA Perez Cancer Immunology, Immunotherapy 68 (10), 1671-1680, 2019 | 58 | 2019 |
| IGF2BP1 Expression in Human Mesenchymal Stem Cells Significantly Affects Their Proliferation and Is Under the Epigenetic Control of TET1/2 Demethylases LG Mahaira, O Katsara, E Pappou, EG Iliopoulou, S Fortis, A Antsaklis, ... Stem cells and development 23 (20), 2501-2512, 2014 | 55 | 2014 |
| Coagulation abnormalities in renal pathology of chronic kidney disease: the interplay between blood cells and soluble factors EG Pavlou, HT Georgatzakou, SP Fortis, KA Tsante, AG Tsantes, ... Biomolecules 11 (9), 1309, 2021 | 51* | 2021 |
| Red blood cell abnormalities as the mirror of SARS-CoV-2 disease severity: a pilot study A Bouchla, AG Kriebardis, HT Georgatzakou, SP Fortis, TP Thomopoulos, ... Frontiers in physiology 12, 825055, 2022 | 45 | 2022 |
| Promising biomarkers in head and neck cancer: the most clinically important miRNAs AC Thomaidou, P Batsaki, M Adamaki, M Goulielmaki, CN Baxevanis, ... International journal of molecular sciences 23 (15), 8257, 2022 | 39 | 2022 |
| In Situ Characterization of Follicular Helper CD4 T Cells Using Multiplexed Imaging K Ioannidou, DR Ndiaye, A Noto, C Fenwick, SP Fortis, G Pantaleo, ... Frontiers in immunology 11, 607626, 2021 | 32 | 2021 |
| Blood cell-derived microvesicles in hematological diseases and beyond HT Georgatzakou, SP Fortis, EG Papageorgiou, MH Antonelou, ... Biomolecules 12 (6), 803, 2022 | 31 | 2022 |
| DNA damage response mechanisms in head and neck cancer: significant implications for therapy and survival C Papalouka, M Adamaki, P Batsaki, P Zoumpourlis, A Tsintarakis, ... International Journal of Molecular Sciences 24 (3), 2760, 2023 | 30 | 2023 |
| Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model SP Fortis, LG Mahaira, EA Anastasopoulou, IF Voutsas, SA Perez, ... Cancer Immunology, Immunotherapy 66 (12), 1631-1642, 2017 | 23 | 2017 |
| Circulating plasma cell-free DNA (cfDNA) as a predictive biomarker for radiotherapy: results from a prospective trial in head and neck cancer MI Koukourakis, E Xanthopoulou, IM Koukourakis, SP Fortis, N Kesesidis, ... Cancer Diagnosis & Prognosis 3 (5), 551, 2023 | 19 | 2023 |
| Prostate cancer: any room left for immunotherapies? CN Baxevanis, SP Fortis, SA Perez Immunotherapy 11 (2), 69-74, 2019 | 19 | 2019 |
| A current synopsis of the emerging role of extracellular vesicles and micro-RNAs in pancreatic cancer: a forward-looking plan for diagnosis and treatment EM Trifylli, AG Kriebardis, E Koustas, N Papadopoulos, SP Fortis, ... International Journal of Molecular Sciences 25 (6), 3406, 2024 | 17 | 2024 |
| The arising role of extracellular vesicles in cholangiocarcinoma: a rundown of the current knowledge regarding diagnostic and therapeutic approaches EM Trifylli, AG Kriebardis, E Koustas, N Papadopoulos, S Vasileiadi, ... International journal of molecular sciences 24 (21), 15563, 2023 | 17 | 2023 |
| Serum miRNA-based distinct clusters define three groups of breast cancer patients with different clinicopathological and immune characteristics SP Fortis, CK Vaxevanis, LG Mahaira, M Sofopoulos, NN Sotiriadou, ... Cancer Immunology, Immunotherapy 68 (1), 57-70, 2019 | 17 | 2019 |
| The thin red line between the immune system and cancer evolution CN Baxevanis, M Goulielmaki, M Adamaki, SP Fortis Translational Oncology 27, 101555, 2023 | 16 | 2023 |
| Potential prognostic molecular signatures in a preclinical model of melanoma SP Fortis, EA Anastasopoulou, IF Voutsas, CN Baxevanis, SA Perez, ... Anticancer research 37 (1), 143-148, 2017 | 16 | 2017 |
